United States Federal Trade Commission
PBMs and FTC Battle in Court Over In-House Insulin Pricing Challenge Intensifies
PBMs; FTC; insulin pricing; rebate schemes; antitrust lawsuit; administrative proceedings; drug affordability; Caremark Rx; Express Scripts; OptumRx
Delaware Court Denies Pfizer’s Bid to Block Novo Nordisk-Metsera Deal
Delaware Court; Pfizer; Novo Nordisk; Metsera; temporary restraining order; merger agreement; antitrust; FTC; obesity drugs
FTC Targets Pharmacy Benefit Managers Over Exorbitant Price Hikes on Specialty Generic Drugs
FTC, Pharmacy Benefit Managers, PBM, Specialty Generic Drugs, Price Hikes, Healthcare Costs
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust
Senators Wyden and Brown Call for FTC Investigation into PBM “Co-Manufacturing” Practices
PBM reforms, FTC investigation, co-manufacturing, pharmacy benefit managers, drug costs, competition, healthcare industry
Senators Wyden and Brown Urge FTC to Expand Investigation into PBMs’ Anti-Competitive Practices
Pharmacy Benefit Managers (PBMs), Anti-Competitive Practices, FTC Investigation, Co-Manufacturing Agreements, Drug Prices, Healthcare Reform
Cigna Challenges FTC’s Report on Pharmacy Benefit Managers, Alleging Unconstitutional Actions and Misleading Claims
Cigna, FTC, Pharmacy Benefit Managers (PBMs), Express Scripts, Unconstitutional Report, Misleading Claims, Drug Prices, Healthcare System
Cigna’s Express Scripts Files Lawsuit Against FTC Over Allegedly Biased PBM Report
Express Scripts, FTC, PBM Report, Lawsuit, Biased, Erroneous, Drug Prices, Healthcare
FTC Supports FDA’s Simplified Biosimilar Interchangeability Plan
biosimilars, interchangeable biosimilars, FDA, FTC, pharmaceutical competition, drug pricing